The company’s newly patented platform utilizes machine learning and fragmentomic analysis to improve early cancer detection accuracy from blood samples.
Strand Life Sciences, a subsidiary of Reliance Industries Ltd, announced on Tuesday that it has obtained an Indian patent for a computational pipeline designed to detect early-stage malignancy through liquid biopsy. The methodology leverages a combination of high-fidelity genome sequencing, biologically informed methylation analysis, and fragmentomic feature extraction to isolate tumor-derived DNA from peripheral blood samples.
The underlying architecture utilizes machine learning to classify cancer presence and determine the tissue of origin based on these extracted features. By integrating methylation patterns—chemical modifications on DNA that serve as reliable biomarkers—the platform aims to mitigate the high failure rates often associated with traditional sequencing approaches. The system employs rigorous quality control protocols to ensure the integrity of the genomic data before it enters the classification layer.
This patent covers specific computational techniques that identify tumor-derived DNA, which is typically present in trace amounts within the bloodstream. The integration of fragmentomics allows the model to analyze the size distribution of cell-free DNA fragments, providing additional signal density for the machine learning classifier. The company asserts that this multi-omic approach significantly improves the sensitivity of detection compared to standard genomic sequencing alone.
The technical implementation involves a multi-stage pipeline where raw sequencing data undergoes normalization to account for batch effects and sequencing bias. By mapping fragment length distributions, the algorithm distinguishes between healthy cell-free DNA and shorter, tumor-derived fragments that characterize early-stage oncogenesis. This feature extraction process is critical for maintaining high specificity in low-abundance scenarios where signal-to-noise ratios are inherently challenging.
The platform addresses a critical bottleneck in oncology diagnostics, where current screening programs fail to identify a large proportion of cases until they reach advanced stages. According to data from the Global Cancer Observatory and the Indian Council of Medical Research, India reports approximately 1.5 million new cancer cases annually, with late-stage diagnosis remaining a primary driver of poor clinical outcomes. The scalability of this genomics-based approach is contingent upon the continued reduction in sequencing costs and the optimization of computational pipelines.
Strand Life Sciences, which originated as a spin-out from the Indian Institute of Science, emphasizes that the platform is designed to function without requiring extensive expansion of local healthcare infrastructure. The model relies on the decreasing cost of high-throughput sequencing, which has seen a roughly 50% decline over the past five years. This economic shift is projected to drive the Indian genomics testing market to a valuation of $2 billion by 2030.
Ramesh Hariharan, chief executive at Strand Life Sciences, noted the technical focus of the development in a recent statement.
This patent reflects our commitment to developing scientifically rigorous, AI-enabled liquid biopsy technologies that can help detect cancer earlier from a simple blood sample. We believe this innovation represents an important step towards making precision cancer screening more accurate, scalable, and accessible.
The company’s strategy hinges on the efficacy of its feature extraction algorithms to maintain high specificity in diverse patient populations.
The significance of this development lies in the transition toward data-driven diagnostic tools that reduce reliance on invasive biopsy procedures. By formalizing the intellectual property surrounding its integrated sequencing and machine learning pipeline, the company establishes a framework for clinical validation in large-scale screening environments. The technical challenge remains the refinement of the classification models to ensure robustness across varying tumor types and stages.
This patent underscores a shift in diagnostic oncology toward high-throughput computational analysis of circulating biomarkers. By moving away from single-analyte testing toward integrated multi-omic models, the industry is prioritizing the detection of subtle genomic signatures that precede clinical symptoms. Future deployments will likely focus on optimizing the computational overhead of the methylation analysis to facilitate faster turnaround times.
Analysts will monitor how the integration of these fragmentomic features performs in prospective clinical trials compared to existing diagnostic benchmarks. The evolution of this platform demonstrates how machine learning is replacing traditional, labor-intensive diagnostic workflows with automated, scalable genomic pipelines. The company intends to leverage this intellectual property to standardize early detection protocols across diverse clinical settings.
